Hepatitis C is an inflammation of the liver caused by a virus. It is primarily spread through blood and blood products, infected needles and from a pregnant mother to baby.
Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400 COVID-19.
Results suggest a high prevalence of fatty liver in adults with chronic HCV, which was significantly associated with central obesity, elevated blood pressure, and metabolic syndrome.
Retreatment with voxilaprevir/velpatasvir/sofosbuvir in patients with HCV and prior DAA failure is effective but may be impacted by hepatocellular carcinoma, cirrhosis, and genotype 3.